GENIUS II

  • Research type

    Research Study

  • Full title

    Gynaecologic organ segmentation and motion tracking using ultrasound Part 2

  • IRAS ID

    281493

  • Contact name

    Susan Lalondrelle

  • Contact email

    susan.lalondrelle@rmh.nhs.uk

  • Sponsor organisation

    CCR R&D

  • Clinicaltrials.gov Identifier

    NCT00000000

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    This study explores the use of ultrasound imaging to improve radiotherapy for cervical cancer. Radiotherapy is an effective treatment, but up to 30% of patients will experience radiation-induced side effects. Published evidence supports the idea that adapting the radiotherapy plan on a daily basis to reflect changes in anatomy can lead to reduction in side-effects and improvement in cure rates. To select the correct plan, a method of visualising the uterus and cervix (uterocervix) is required. Currently, an imaging method called cone beam computed tomography (CBCT) is used to visualise the uterocervix immediately before treatment. By looking at these images the clinical staff (radiographers) responsible for delivering treatment can select the best treatment plan for that day. Sometimes it can be very hard to see the uterocervix using CBCT due to poor image quality. Ultrasound is a safe and cost-effective modality for imaging soft tissues such as the uterus. This study will examine the use of ultrasound imaging to visualise the uterocervix to help radiographers select of the best treatment each day. We will ask patients undergoing standard radiotherapy for cervical cancer to receive ultrasound imaging prior to CT scanning and treatment. Ultrasound images will be combined with CBCT images (US-CBCT) to see if adding ultrasound allows radiographers to more often select the correct treatment and have more confidence in their selection. We will also explore using ultrasound only to help select the treatment, as CBCT is not universally available worldwide. Using the imaging data collected during treatment, we will find out how often the correct treatment plan would have been selected if using US or US-CBCT compared to using CBCT alone.

  • REC name

    West Midlands - Solihull Research Ethics Committee

  • REC reference

    22/WM/0056

  • Date of REC Opinion

    30 Mar 2022

  • REC opinion

    Further Information Favourable Opinion